Rigel Pharmaceuticals (RIGL)
(Delayed Data from NSDQ)
$1.10 USD
-0.03 (-2.22%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $1.09 -0.01 (-0.91%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
RIGL 1.10 -0.03(-2.22%)
Will RIGL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for RIGL based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RIGL
Silence Therapeutics (SLN) Surges 5.7%: Is This an Indication of Further Gains?
Rigel Pharmaceuticals (RIGL) Reports Break-Even Earnings for Q4
RIGL: What are Zacks experts saying now?
Zacks Private Portfolio Services
OmniAb, Inc. (OABI) Soars 10.5%: Is Further Upside Left in the Stock?
BioCryst Pharmaceuticals (BCRX) Reports Q4 Loss, Tops Revenue Estimates
Can Rigel Pharmaceuticals (RIGL) Beat Q4 Earnings Estimates?
Other News for RIGL
12 Health Care Stocks Moving In Monday's After-Market Session
Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma
Rigel Pharmaceuticals' olutasidenib shows efficacy in published AML study
Commit To Buy Rigel Pharmaceuticals At $1, Earn 20.1% Annualized Using Options